Journal of ethnopharmacology · 2025
Jujuboside A in ameliorating insomnia in mice via GABAergic modulation of the PVT.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Mingyu, Wang Gen, Zhao Maoyuan, Hou Lingyun, Ma Dongchuan, Yang Hao, Luo Zhaoliang, Mi Benzhong, Lv Shangbin
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Ziziphus jujuba var. spinosa (Bunge) Hu ex H. F. Chow (ZSS), a traditional Chinese medicinal herb, has been historically used to treat insomnia and neurological disorders. Jujuboside A, a triterpenoid saponin isolated from ZSS, represents its core bioactive component with purported sedative properties, yet its mechanism of action remains underexplored.
AIM OF THE STUDY: To validate the anti-insomnia efficacy of Jujuboside A and elucidate its GABAergic regulatory mechanisms through integrated in vivo and in vitro approaches.
MATERIALS AND METHODS: A chronic sleep deprivation mouse model was established using modified multi-platform water environment. Behavioral assessments (open-field test, pentobarbital-induced sleep test) were combined with histopathological analysis (H&E staining), flow cytometry (apoptosis), ELISA (GABA/Glu quantification), and Western blot (GABA A/GABA B, NMDA/AMPA receptors). Pharmacological inhibition of GABA signaling was performed using GABA-IN-1.
RESULTS: Jujuboside A significantly shortened sleep latency and prolonged sleep duration vs. model group. Histopathology revealed Jujuboside A-mediated restoration of hippocampal neuronal density and mitigation of nuclear pyknosis. Jujuboside An upregulated GABA levels while suppressing Glu and neuronal apoptosis, with concomitant increases in GABA A and GABA B receptor expression. Crucially, GABA-IN-1 abolished these therapeutic effects, confirming GABA dependency.
CONCLUSIONS: Jujuboside A ameliorates insomnia by restoring GABA/Glu homeostasis and enhancing GABA receptor expression, thereby validating ZSS's traditional use through modern pharmacological evidence.
AIM OF THE STUDY: To validate the anti-insomnia efficacy of Jujuboside A and elucidate its GABAergic regulatory mechanisms through integrated in vivo and in vitro approaches.
MATERIALS AND METHODS: A chronic sleep deprivation mouse model was established using modified multi-platform water environment. Behavioral assessments (open-field test, pentobarbital-induced sleep test) were combined with histopathological analysis (H&E staining), flow cytometry (apoptosis), ELISA (GABA/Glu quantification), and Western blot (GABA A/GABA B, NMDA/AMPA receptors). Pharmacological inhibition of GABA signaling was performed using GABA-IN-1.
RESULTS: Jujuboside A significantly shortened sleep latency and prolonged sleep duration vs. model group. Histopathology revealed Jujuboside A-mediated restoration of hippocampal neuronal density and mitigation of nuclear pyknosis. Jujuboside An upregulated GABA levels while suppressing Glu and neuronal apoptosis, with concomitant increases in GABA A and GABA B receptor expression. Crucially, GABA-IN-1 abolished these therapeutic effects, confirming GABA dependency.
CONCLUSIONS: Jujuboside A ameliorates insomnia by restoring GABA/Glu homeostasis and enhancing GABA receptor expression, thereby validating ZSS's traditional use through modern pharmacological evidence.